James R. Kasinger, the General Counsel and Secretary of CRISPR Therapeutics AG (NASDAQ:CRSP), reported a sale of 1,089 common shares valued at approximately $50,398, according to a recent SEC filing. The transaction took place on October 14, 2024, at a price of $46.28 per share.
In addition to the sale, Kasinger acquired 2,113 common shares on October 13, 2024, through the vesting of restricted stock units. This acquisition did not involve any cash transaction. Following these transactions, Kasinger holds 62,597 shares of CRISPR Therapeutics directly.
The sale was executed to cover tax obligations related to the vesting of restricted stock units, as mandated by the company's RSU Settlement Policy, and was not a discretionary trade.
In other recent news, CRISPR Therapeutics has faced a series of analyst adjustments following its second-quarter earnings. TD Cowen maintained a Sell rating on CRISPR Therapeutics, citing no revenue from the company's gene-editing therapy, Casgevy, in the second quarter. The firm also noted a need for a significant rise in patient numbers for Casgevy to impact its commercial success. Similarly, Stifel and RBC Capital Markets revised their price targets for CRISPR Therapeutics due to a cautious outlook on the company's near-term revenue prospects and upcoming clinical data.
In contrast, Needham reduced its stock price target for CRISPR Therapeutics but maintained a Buy rating, reflecting confidence in the company's long-term potential despite a lack of Casgevy sales. The firm revised its sales projections for Casgevy, forecasting $17 million for fiscal year 2024. Meanwhile, Piper Sandler maintained its Overweight rating and a consistent price target of $105, highlighting the progression of CRISPR's Phase I/II study for its allogeneic CD19 CAR-T therapy, CTX112.
CRISPR Therapeutics is also expected to release initial data for another therapy, CTX110, aimed at treating large B-cell lymphoma (LBCL), by the end of the year. In addition, the company is advancing its pipeline with CTX131 and CTX112, which have entered Phase I studies. These are recent developments in the ongoing efforts of CRISPR Therapeutics to advance its gene-editing pipeline.
InvestingPro Insights
As CRISPR Therapeutics AG (NASDAQ:CRSP) navigates its financial landscape, recent InvestingPro data provides additional context to James R. Kasinger's stock transactions. The company's market capitalization stands at $4.27 billion, reflecting its significant presence in the biotech sector. Despite a challenging year with a year-to-date price total return of -23.24%, CRISPR Therapeutics has shown resilience with a 1-year price total return of 8.44%.
InvestingPro Tips highlight that CRISPR Therapeutics holds more cash than debt on its balance sheet, which could provide financial flexibility as the company continues its research and development efforts. Additionally, liquid assets exceed short-term obligations, potentially mitigating near-term financial risks.
However, investors should note that analysts anticipate a sales decline in the current year, and the company is not expected to be profitable this year. These factors may influence executive stock transactions and company strategy moving forward.
For a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide deeper insights into CRISPR Therapeutics' financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.